



PHARMACODYNAMICS II

Quantitative aspects of drugs



Prof. hanan Hagar

Ilos

Determine quantitative aspects of drug receptor binding.


Recognize concentration binding curves.

Identify dose response curves and the therapeutic utility of these curves.

Classify different types of antagonism



QUANTIFY ASPECTS OF DRUG ACTION



Relate concentration [C] of **D** used (x- axis) to the **binding capacity** at receptors (y-axis)

Relate concentration [C] of **D** used (x- axis) to **response** produced (y-axis)

Concentration-Binding Curve

Dose Response Curves

AFFINITY

EFFICACY

POTENCY

The tendency of a drug to bind to the receptors is governed by its *affinity*.

AFFINITY

The ability for it, once bound, to activate the receptor is denoted by its *efficacy*.

EFFICACY



Relate concentration [C] of **D** used (x- axis) to **binding capacity** [B] at receptors (y-axis)

Relate [C] of **D** used (x- axis) to the **response** [R] produced (y-axis)

AFFINITY

EFFICACY

Concentration-Binding Curve

Dose Response Curve

POTENCY

Concentration binding curves

Is a correlation between **drug concentration** [C] used (x- axis) and **drug binding** capacity at receptors [B] (y-axis).

i.e. **Affinity** :

is relation between concentration & drug binding

Concentration-Binding curves are used to determine:

○ B_{\max} (the binding capacity)

is the total density of receptors in the tissues.

○ K_{D50}



is the concentration of the drug required to occupy 50% of receptors at equilibrium.

○ The affinity of drug for receptor

The higher the affinity of D for receptor, the lower is the K_D **i.e. inverse relation**

Concentration-Binding Curve

(B_{max}) : Total density of receptors in the tissue



$(k_D) = [C]$ of **D** required to occupy 50% of receptors at equilibrium



Dose -response curves

- Used to study how response varies with the concentration of the drug or dose.
- Is a correlation between drug concentration [D] used (x- axis) and drug response [R] (y-axis).
- **i.e. relation between concentration & Response**



TYPES of Dose -response curves

- ✓ Graded dose-response curve
- ✓ Quantal dose-response curve

Graded Dose-response Curve

- **Relate drug concentration to response.**
- **Gradual increase in response by increasing the dose**
- **Response is gradual and continuous.**
- **e.g. ↓blood pressure, heart rate, blood glucose level, cholesterol,...**
- **Curve is usually sigmoid in shape**

GRADED DOSE RESPONSE CURVE



Graded dose-response curves are used to determine:

Graded dose-response curves are used to calculate:

- **Efficacy**
- E_{\max}
- EC_{50}
- **Potency**

Maximum Efficacy (E_{\max}): is the maximal biological response produced by a drug.

Median Effective concentration (EC_{50}):


○ is the concentration of the drug that produces a response equal to 50% of the maximal response (E_{\max}).


Graded dose-response curves are used to determine:

Potency: the concentration of drug required to produce a specified response (**50% of the maximal response = EC_{50}**).


Potency of drugs can be compared using EC_{50} ,
The smaller the EC_{50} , the more potent the drug.

Potency is inversely proportional to EC_{50}



A

The EC_{50} is the concentration of the drug that produces a response equal to fifty percent of the maximal response.

B

The potency of drugs can be compared using the EC_{50} , the smaller the EC_{50} the more potent the drug.




Quantal Dose-response Curve

- Relate drug concentration to % percentage of patients responding.
- **all or none response.**
- The response may be **therapeutic response, adverse effect or lethal effect.**
- e.g. prevention of convulsion, arrhythmias or death.
- **Used to determine**
 - ED_{50}
 - TD_{50} & LD_{50}
 - Therapeutic index.

QANTAL DOSE RESPONSE CURVE

All-non response

- * specified therapeutic response
- * adverse response
- * lethal outcome




Dose-frequency relationship

Median Effective Dose (ED₅₀): is a dose of the drug required to produce **a therapeutic effect** in 50% of individuals.

Median Toxic Dose (TD₅₀):
is the dose of a drug required to produce **toxic effects** in 50 % of individuals.

Median Lethal Dose (LD₅₀): is the dose of a drug required to produce **death** in 50 % of individuals.

QANTAL DOSE RESPONSE CURVE: *used to determine*



ED_{50} = 50% of individuals exhibit the specified therapeutic response


TD_{50} = 50% of individuals exhibit toxic effects

LD_{50} = 50% of individuals exhibit death


Therapeutic Index (TI)

- Therapeutic index = $\frac{LD_{50}}{ED_{50}}$
- Is a measure of safety profile
- **Large TI** means drug has wide margin of safety
e.g **diazepam, penicillin**
- **Small TI** = a narrow margin of safety e.g.
digoxin, warfarin

A *Warfarin*: Small therapeutic index



B *Penicillin*: Large therapeutic index



ANTAGONISM

It is the diminution or the complete abolishment of the effect of one drug in the presence of another.

Types

1. Chemical

Two drugs react chemically resulting in loss of activity of active drug. **Dimercaprol** reduces heavy metal toxicity [**lead**]

2. Physiological

Two drugs possess opposing actions in body, so tend to cancel each other's effect. **Adrenaline & histamine**

3. Pharmacokinetic

The antagonist effectively reduces the concentration of the active drug at the site of action

Phenobarbitone accelerates hepatic metabolism **warfarin**

4. Pharmacodynamic (Competitive)

Reversible

Irreversible

5. Pharmacodynamic (Non-Competitive)

Antagonism

It is the decrease or the complete loss of the effect of one drug by the combination with another drug.

Types of Antagonism

- ✓ **Chemical antagonism.**
- ✓ **Physiological antagonism.**
- ✓ **Pharmacokinetic antagonism**
- ✓ **Pharmacodynamic antagonism**
 - **Competitive**
 - **Reversible**
 - **Irreversible**
 - **Non-competitive**

Antagonist

Types

- **Physiological antagonist.**
- **Chemical antagonist.**
- **Pharmacokinetic antagonist.**
- **Pharmacodynamic antagonist.**

Chemical Antagonism

- Simple chemical reaction between two drugs resulting into loss of activity.
- No receptors are involved.
- e.g. **Dimercaprol** used as antidote to reduce heavy metal toxicity (**lead toxicity**).

Pharmacokinetic Antagonism

- The antagonist effectively reduces the concentration of the active drug at the site of action.
- e.g. **Phenobarbitone** accelerates hepatic metabolism of warfarin

Physiological Antagonism

- **Two drugs act on different receptors to produce opposite physiological effects.**
- **e.g. Adrenaline is used in anaphylactic shock**

Histamine →

vasodilatation (↓BP) & bronchoconstriction


Adrenaline →

Vasoconstriction (↑ BP) & bronchodilation.

Pharmacodynamic antagonism

Competitive (reversible)

- **Two drugs compete for the same receptor (only one is bound).**
- **The antagonist partially or completely prevents the pharmacological effect of agonist.**
- **Antagonist dissociate rapidly from receptor.**
- **Antagonism can be overcome by increasing the concentration of the agonist.**
- **Parallel shift of the D-R curve to the right, without any change in slope or maximum.**
- **e.g. acetylcholine and atropine.**



Pharmacodynamic antagonism


Competitive (irreversible)

- Two drugs compete for the same receptor.
- **Antagonist** forms stable, permanent chemical bond with receptor.
- The original response can not be overcome even by increasing the dose of the agonist.
- No parallel shift of D-R curve
- a decrease in slope and a reduced maximal response are obtained.

e.g. phenoxybenzamine and noradrenaline.


Competitive Antagonism

Reversible



Parallel shift to the right, without any change in slope or maximum

Irreversible



No parallel shift

But both a decrease in slope and a reduced maximum are obtained.

Competitive (reversible)

- Two drugs compete for the same receptor.
- Antagonist dissociate rapidly from receptor.
- The original response can be obtained by increasing the concentration of the agonist.
- Parallel shift to the right
- No change in slope
- No change in maximum effect

e.g. acetylcholine and atropine.

Competitive (irreversible)

- Two drugs compete for the same receptor.
- **Antagonist** forms stable, permanent chemical bond with receptor.
- The original response can not be obtained even by increasing the dose of the agonist.
- No parallel shift
- A decrease in slope
- Decrease in maximum effect

e.g. phenoxybenzamine and noradrenaline.

COMPETATIVE ANTAGONISM

Reversible

Antagonist readily dissociate from binding site of **agonist** to the receptor

Antagonism can be overcome by increasing concentration of agonist

Atropine vs Ach

Irreversible

Antagonist form stable, permanent / near permanent chemical bond with receptor.

Inactivation lasts for duration of receptor turnover or its de-novo synthesis → explains its longevity of action

Phenoxybenzamine & Noradrenaline

Pharmacodynamic antagonism

Non-competitive

- **Agonist** and **Antagonist** can bound simultaneously.
- Antagonist block at some point the chain of events that stimulate the response of agonist.
- Antagonism cannot be overcome by increasing concentration of agonist .

e.g. verapamil and noradrenaline.

ANTAGONISM

Non-Competitive


Agonist and Antagonist can be bound simultaneously the response of agonist

Receptor Blockade
Competitive

Reversible
Agonist and Antagonist compete

Antagonist to the = competes with

Irreversible




Competitive vs Noncompetitive Antagonism

Antagonism can be overcome by increasing concentration of agonist =

SURMOUNTABLE

Effect



Antagonism cannot be overcome by increasing concentration of agonist = **NON-SURMOUNTABLE**

ANTAGONISM

Non-Competitive

Antagonist block at some point the chain of events that ignite the response of **agonist**

Agonist and **Antagonist** can be bound simultaneously


Receptor Blockade
(Competitive)

Antagonist prevents binding of **agonist** to the receptor at the same binding site (= competes with it at same receptor)

Agonist and **Antagonist** compete (only one is bound)

Reversible

Irreversible





G L W
O O C
O O K
D

PHARMACOLOGY